Prototype Quantitative Assay for Fibrinogen/Fibrin Degradation Products

Clinical Evaluation

Samuel H. Sigal, George S. Cembrowski, Sanford J. Shattil, Nancy M. Brown, Richard S. Schifreen, Mark W. Schwartz

Research output: Contribution to journalArticle

Abstract

A new quantitative assay for fibrinogen/fibrin degradation products (FDPs) was clinically evaluated in 123 tertiary-care patients for whom the standard semiquantitative FDP assay had previously been ordered. On the basis of a comprehensive chart review, 24 patients were categorized as having disseminated intravascular coagulation (DIC), 84 were considered not to have had DIC, ten had fibrinolysis (nine of ten streptokinase induced), and five had a complicated coagulopathy whose exact nature could not be determined. The quantitative and semiquantitative FDP values were significantly correlated. However, the FDP level indicative of DIC was lower by the quantitative assay than by the semiquantitative assay, approximately 18 mg/L vs 40 mg/L, respectively. The advantages of the quantitative over the semiquantitative assay included improved precision and ability to closely monitor changes in the severity of the coagulopathy.

Original languageEnglish (US)
Pages (from-to)1790-1793
Number of pages4
JournalArchives of Internal Medicine
Volume147
Issue number10
DOIs
StatePublished - 1987
Externally publishedYes

Fingerprint

Fibrin Fibrinogen Degradation Products
Disseminated Intravascular Coagulation
Streptokinase
Fibrinolysis
Tertiary Healthcare

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Prototype Quantitative Assay for Fibrinogen/Fibrin Degradation Products : Clinical Evaluation. / Sigal, Samuel H.; Cembrowski, George S.; Shattil, Sanford J.; Brown, Nancy M.; Schifreen, Richard S.; Schwartz, Mark W.

In: Archives of Internal Medicine, Vol. 147, No. 10, 1987, p. 1790-1793.

Research output: Contribution to journalArticle

Sigal, Samuel H. ; Cembrowski, George S. ; Shattil, Sanford J. ; Brown, Nancy M. ; Schifreen, Richard S. ; Schwartz, Mark W. / Prototype Quantitative Assay for Fibrinogen/Fibrin Degradation Products : Clinical Evaluation. In: Archives of Internal Medicine. 1987 ; Vol. 147, No. 10. pp. 1790-1793.
@article{bce662592ed647c1847e5a82480735de,
title = "Prototype Quantitative Assay for Fibrinogen/Fibrin Degradation Products: Clinical Evaluation",
abstract = "A new quantitative assay for fibrinogen/fibrin degradation products (FDPs) was clinically evaluated in 123 tertiary-care patients for whom the standard semiquantitative FDP assay had previously been ordered. On the basis of a comprehensive chart review, 24 patients were categorized as having disseminated intravascular coagulation (DIC), 84 were considered not to have had DIC, ten had fibrinolysis (nine of ten streptokinase induced), and five had a complicated coagulopathy whose exact nature could not be determined. The quantitative and semiquantitative FDP values were significantly correlated. However, the FDP level indicative of DIC was lower by the quantitative assay than by the semiquantitative assay, approximately 18 mg/L vs 40 mg/L, respectively. The advantages of the quantitative over the semiquantitative assay included improved precision and ability to closely monitor changes in the severity of the coagulopathy.",
author = "Sigal, {Samuel H.} and Cembrowski, {George S.} and Shattil, {Sanford J.} and Brown, {Nancy M.} and Schifreen, {Richard S.} and Schwartz, {Mark W.}",
year = "1987",
doi = "10.1001/archinte.1987.00370100104017",
language = "English (US)",
volume = "147",
pages = "1790--1793",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "10",

}

TY - JOUR

T1 - Prototype Quantitative Assay for Fibrinogen/Fibrin Degradation Products

T2 - Clinical Evaluation

AU - Sigal, Samuel H.

AU - Cembrowski, George S.

AU - Shattil, Sanford J.

AU - Brown, Nancy M.

AU - Schifreen, Richard S.

AU - Schwartz, Mark W.

PY - 1987

Y1 - 1987

N2 - A new quantitative assay for fibrinogen/fibrin degradation products (FDPs) was clinically evaluated in 123 tertiary-care patients for whom the standard semiquantitative FDP assay had previously been ordered. On the basis of a comprehensive chart review, 24 patients were categorized as having disseminated intravascular coagulation (DIC), 84 were considered not to have had DIC, ten had fibrinolysis (nine of ten streptokinase induced), and five had a complicated coagulopathy whose exact nature could not be determined. The quantitative and semiquantitative FDP values were significantly correlated. However, the FDP level indicative of DIC was lower by the quantitative assay than by the semiquantitative assay, approximately 18 mg/L vs 40 mg/L, respectively. The advantages of the quantitative over the semiquantitative assay included improved precision and ability to closely monitor changes in the severity of the coagulopathy.

AB - A new quantitative assay for fibrinogen/fibrin degradation products (FDPs) was clinically evaluated in 123 tertiary-care patients for whom the standard semiquantitative FDP assay had previously been ordered. On the basis of a comprehensive chart review, 24 patients were categorized as having disseminated intravascular coagulation (DIC), 84 were considered not to have had DIC, ten had fibrinolysis (nine of ten streptokinase induced), and five had a complicated coagulopathy whose exact nature could not be determined. The quantitative and semiquantitative FDP values were significantly correlated. However, the FDP level indicative of DIC was lower by the quantitative assay than by the semiquantitative assay, approximately 18 mg/L vs 40 mg/L, respectively. The advantages of the quantitative over the semiquantitative assay included improved precision and ability to closely monitor changes in the severity of the coagulopathy.

UR - http://www.scopus.com/inward/record.url?scp=0023194289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023194289&partnerID=8YFLogxK

U2 - 10.1001/archinte.1987.00370100104017

DO - 10.1001/archinte.1987.00370100104017

M3 - Article

VL - 147

SP - 1790

EP - 1793

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 10

ER -